For solid tumor models, including brain tumors, the pan-PI3K inhibitor pilaralisib was tested against 38 models of multiple histologies, the PI3K and mTOR inhibitor voxtalisib was tested against 2 GBM models, and the pan-PI3K inhibitor copanlisib was tested against 6 osteosarcoma models (Reynolds et al., 2013). This evidence concerns the gene PIK3CA and osteosarcoma.